⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
businesswire.com
AGEN
Pancreatic Cancer - Drug Pipeline Insight, 2026 | 170+ Companies and 200+ Therapies Signal Licensing, Investment, and Immuno-Oncology Growth Opportunities
globenewswire.com
MRKR
VRTX
ABUS
AGEN
IMUX
CANF
Agenus to Participate in Chardan’s 10 th Annual Healthcare Investor Conference
businesswire.com
AGEN
アルメニア、既治療のMSS転移性大腸がんを対象にアジーナスのBOT+BALを世界で初めて販売承認
businesswire.com
AGEN
Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026
businesswire.com
AGEN
Agenus annonce à l'IGCS 2026 une survie à trois ans estimée à 48 % avec BOT+BAL dans le cancer de l'ovaire récurrent
businesswire.com
AGEN
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
businesswire.com
AGEN
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
businesswire.com
AGEN
Agenus to Participate in Upcoming September Investor Conferences
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN